Stay updated with breaking news from Fabry Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dosing of patients in Phase 3 AFFINE trial to support primary analysis complete; pivotal data read-out expected in mid-2024; BLA and MAA submissions anticipated in second half of 2024. ... | April 26, 2023
Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in... | June 18, 2023
Sangamo Therapeutics, Inc. (NASDAQ:NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief...
SGMO earnings call for the period ending October 3, 2021.